ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos2.2 B2.08 B2.14 B2.16 B2.35 B8.73 BInvestigación y desarrollo374 M342 M352 M346 M357 M1.4 BBeneficio operativo2.02 B1.72 B1.83 B1.94 B2.25 B7.75 BTotal de ingresos no operativos255 M208 M275 M240 M271 M994 MGastos por intereses, netos de intereses capitalizados317 M303 M404 M347 M365 M1.42 BIngresos no operativos, una vez deducidos los gastos por intereses-75 M-98 M-110 M-105 M-100 M-413 MIngresos/gastos extraordinarios13 M3 M-19 M-2 M6 M-12 MBeneficio antes de impuestos1.97 B1.61 B1.71 B1.83 B2.12 B7.27 BParticipación en los beneficios33 M-14 M2 M2 M-31 M-41 MImpuestos149 M95 M92 M207 M153 M547 MParticipación minoritaria-7 M4 M2 M5 M6 M17 MOtros ingresos/gastos después de impuestos-254 M-135 M-63 M-117 M-140 M-455 MBeneficio neto antes de actividades interrumpidas1.83 B1.51 B1.62 B1.62 B1.96 B6.7 BOperaciones suspendidas——————Beneficio neto1.83 B1.51 B1.62 B1.62 B1.96 B6.7 BAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas1.83 B1.51 B1.62 B1.62 B1.96 B6.7 BBeneficio básico por acción4.83.994.284.285.2217.77Beneficio por acción diluido4.783.984.284.275.2117.74Número medio de acciones ordinarias382 M378 M378 M378 M377 M1.51 BAcciones diluidas383 M379 M378 M378 M378 M1.51 BEBITDA4.27 B2.42 B2.95 B3.46 B4.28 B13.11 BEBIT2.02 B1.72 B1.83 B1.94 B2.26 B7.75 BCosto de los ingresos——————Otros costes de producción——————Amortización y depreciación (flujo de caja)2.26 B705 M1.11 B1.52 B2.02 B5.36 B
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. is an American life science and clinical research company. It is a global supplier of analytical instruments, clinical development solutions, specialty diagnostics, laboratory, pharmaceutical and biotechnology services. Based in Waltham, Massachusetts, Thermo Fisher was formed through the merger of Thermo Electron and Fisher Scientific in 2006. Thermo Fisher Scientific has acquired other reagent, consumable, instrumentation, and service providers, including Life Technologies Corporation, Alfa Aesar, Affymetrix, FEI Company, BD Advanced Bioprocessing, and PPD.
It ranked 104th on the Fortune 500 list based on its 2024 annual revenue of $42.879 billion.
Thermo Fisher announced a $2 billion investment over four years in the U.S., including $1.5 billion for expanding manufacturing capacity and $500 million for R&D investment. This initiative aims to bolster domestic biotech manufacturing, create high-paying jobs, and reinforce the U.S. healthcare supply chain.